文献速递中医内科中药与中成药合理使用

逍遥丸治疗轻中度抑郁的随机临床试验及DNA甲基化分析

Xiaoyao Pills, a Chinese patent medicine, treats mild and moderate depression: A randomized clinical trial combined with DNA methylation analysis.
PubMed 文献 · Phytomedicine · 2024-04-20

本研究为双盲随机安慰剂对照试验,评估口服逍遥丸治疗抑郁的疗效与表观遗传机制。结果显示逍遥丸有效缓解轻中度抑郁症状,尤其改善精神运动性迟缓,并恢复与抑郁相关的异常基因表达和DNA甲基化模式。

要点

  • 逍遥丸可有效缓解轻中度抑郁症状,尤其改善精神运动性迟缓。
  • 逍遥丸恢复抑郁相关的异常基因表达和DNA甲基化模式。
  • DNA甲基化正常化与多个基因下调相关,并涉及DNMT1表达增加。

核心结论

  • 逍遥丸有效缓解轻中度抑郁症状,尤其改善精神运动性迟缓。
  • 逍遥丸恢复抑郁相关的异常基因表达和DNA甲基化模式。
  • DNA甲基化改变与DNA甲基转移酶DNMT1表达增加相关。

研究设计与样本

  • 双盲、随机、安慰剂对照临床试验。
  • 采用HAMD-17量表在基线和治疗后每2周记录评分。
  • 对外周血白细胞进行mRNA测序和全基因组DNA甲基化测序。

主要发现

  • 逍遥丸有效缓解轻中度抑郁障碍患者症状,尤其精神运动性迟缓。
  • 逍遥丸恢复抑郁相关的异常基因表达和DNA甲基化模式。
  • DNA甲基化正常化与多个基因下调相关。
  • 逍遥丸治疗样本的DNA甲基化水平改变归因于DNMT1表达增加。

临床怎么用

  • 逍遥丸可用于轻中度抑郁的治疗,尤其适用于伴精神运动性迟缓的患者。
  • 逍遥丸的治疗效应可能涉及DNA甲基化调控的表观遗传机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Xiaoyao pills (XYP) is a commercial Chinese patent medicine used in the treatment of depression. However, the mechanisms underlying its therapeutic effects, as well as the patients who can benefit from XYP, have not been evaluated so far. OBJECTIVES: To this end, we conducted a double-blinded, random, and placebo-controlled clinical trial of orally administered XYP in patients with depression. METHODS: The 17-item Hamilton Depression Rating Scale (HAMD-17) scores were recorded at baseline, and every 2 weeks after the start of treatment. To further elucidate the epigenetic mechanism of XYP, we performed mRNA sequencing and genome-wide DNA methylation sequencing using peripheral blood leukocytes of patients and healthy. RESULTS: XYP effectively alleviated the symptoms in patients with mild or moderate depressive disorders, particularly that of psychomotor retardation. XYP restored aberrant gene expression and DNA methylation patterns associated with depression, and the normalization of DNA methylation correlated with downregulation of several genes. In addition, altered DNA methylation levels in the XYP-treated samples were attributed to increased expression of the DNA methyltransferase DNMT1. CONCLUSIONS: Our study provides new insights into the epigenetic mechanism underlying depression and the therapeutic effects of XYP, along with an experimental basis for using XYP in the treatment of depression. TRIAL REGISTRATION INFORMATION: The name of the registry and number: U.S. CLINICAL TRIALS REGISTRY: The link to the registration: ClinicalTrials.gov ISRCTN12746343 (https://www.isrctn.com/ISRCTN12746343). The name of the trial register is "Efficacy and safety of the Xiaoyao pill for improving the clinical symptoms of stagnation of liver qi (chi) and spleen deficiency". The clinical trial registration number is ISRCTN12746343.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Fan L, Zeng P, Wang X, et al. Xiaoyao Pills, a Chinese patent medicine, treats mild and moderate depression: A randomized clinical trial combined with DNA methylation analysis. Phytomedicine. 2024. PMID: 38815407. doi:10.1016/j.phymed.2024.155660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。